Relmada Therapeutics, Inc.
RLMD
$0.3819
-$0.0164-4.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.08M | 11.86M | 8.10M | 9.68M | 12.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.08M | 23.01M | 18.82M | 22.99M | 26.83M |
| Operating Income | -19.08M | -23.01M | -18.82M | -22.99M | -26.83M |
| Income Before Tax | -18.66M | -21.73M | -17.77M | -21.83M | -25.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.66M | -21.73M | -17.77M | -21.83M | -25.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.66M | -21.73M | -17.77M | -21.83M | -25.17M |
| EBIT | -19.08M | -23.01M | -18.82M | -22.99M | -26.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.62 | -0.72 | -0.59 | -0.72 | -0.84 |
| Normalized Basic EPS | -0.38 | -0.46 | -0.37 | -0.45 | -0.53 |
| EPS Diluted | -0.62 | -0.72 | -0.59 | -0.72 | -0.84 |
| Normalized Diluted EPS | -0.38 | -0.46 | -0.37 | -0.45 | -0.53 |
| Average Basic Shares Outstanding | 30.17M | 30.17M | 30.17M | 30.13M | 30.10M |
| Average Diluted Shares Outstanding | 30.17M | 30.17M | 30.17M | 30.13M | 30.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |